Eris Lifesciences acquires 51% stake in Swiss Parenterals for ₹637.50 crore

Acquiring Swiss Parenterals will bolster the company's domestic presence with a new injectables-focused branded formulations business and enhance reach in emerging markets Read The Rest at :